miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

Safehold outlines $1.2B liquidity position and targets increased ground lease volume for 2026 while expanding affordable housing platform

View original at seekingalpha.com
Safehold outlines $1.2B liquidity position and targets increased ground lease volume for 2026 while expanding affordable housing platform Earnings Call Insights: Safehold Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Leverage is around 2x and company wants to maintain that level or lower, conducting buybacks in a leverage-neutral way

    80% confidence
  • Excluding nonrecurring items, annual EPS was $1.65, up 5% year-over-year

    80% confidence
  • Quarterly GAAP earnings increase driven by $3.5 million net accretion on investment fundings, offset by $2.2 million loss on early debt extinguishment

    80% confidence
  • Ground lease portfolio grew to $7.1 billion in assets with estimated unrealized capital appreciation at $9.3 billion, a $200 million increase from last quarter

    80% confidence
  • Full year 2025 GAAP revenue was $385.6 million, net income was $114.5 million and EPS was $1.59

    80% confidence
  • Focus areas for 2026 are more consistent origination growth, greater visibility for Carets, and implementation of share buybacks when conditions are favorable

    80% confidence
  • Q4 was productive for new investments and capital markets activity, closing 10 transactions including 9 ground leases and 1 leasehold loan for $167 million aggregate commitment

    80% confidence
  • Management team strengthened with appointment of Michael Trachtenberg as President and expansion of affordable housing team into new states and sponsors

    80% confidence
  • Q4 2025 GAAP revenue was $97.9 million, net income was $27.9 million and earnings per share was $0.39

    80% confidence
  • Portfolio GLTV remained flat quarter-over-quarter at 52%, and rent coverage unchanged at 3.4x

    80% confidence
  • Excluding nonrecurring loss, Q4 EPS was $0.42, up 15% year-over-year

    80% confidence
  • Carets value can be recognized much earlier and represents Safehold's trust fund, seeking ways to enable understanding through liquidity, sales, or monetizations

    80% confidence
  • S&P upgraded Safehold to A- with stable outlook, resulting in single A ratings from all three major agencies

    80% confidence
  • Three areas of focus for 2026: increased ground lease volume versus 2025, recognition of Carets value, and implementation of share buybacks

    80% confidence
  • Progress being made in affordable housing origination outside California with several deals under LOI

    80% confidence
  • Liquidity at year-end approximately $1.2 billion, supported by joint venture capacity

    80% confidence
  • Confident in business model and long-term value creation embedded in diversified portfolio of institutional quality ground leases

    80% confidence
  • Park Hotels litigation court date set for Q1 2027 with expected $7 million in costs to reach resolution

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Safehold outlines $1.2B liquidity position and targets increased ground lease volume for 2026 while expanding affordable housing platform — Source | Via News | es.VIA.NEWS